TORONTO, CANADA / ACCESSWIRE / AUGUST 6, 2019 / Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company developing first-in-class, targeted cancer therapeutics, announced today that The University of Texas MD Anderson Cancer Center (MDACC) has activated an Investigator Initiated Clinical trial of Soricimed’s lead drug candidate, SOR-C13 in late stage pancreatic cancer.
This trial was initiated by Siqing Fu, MD PhD, a member of the Department of Investigational Cancer Therapeutics at MDACC, one of the world’s most respected cancer research centers, based on the results of Soricimed’s multi-center Phase 1 clinical trial in patients with late-stage solid tumor cancer. The Phase 1 trial concluded that SOR-C13 was safe and well tolerated, with preliminary indication of anticancer activity, including tumor regression in two late stage pancreatic cancer patients. The objectives of this Phase 1b investigator-initiated trial are to refine dosing and further explore safety and efficacy of SOR-C13 in late-stage solid tumor cancer.
“We are pleased to be conducting this trial with the support of Soricimed Biopharma Inc.”, stated Principal investigator, Siqing Fu, MD PhD, Professor at the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center. “Pancreatic cancer is a difficult to treat cancer. We were intrigued by the positive efficacy signals we observed in the pancreatic cancer patients treated with SOR-C13 at our site in Soricimed’s Phase 1 clinical trial. With this next trial, among other critical data, we look to expand our data in pancreatic cancer patients and confirm the efficacy results seen earlier.”
“We’re pleased to extend our clinical relationship with MD Anderson in advancing our understanding of the potential of SOC-C13 to treat pancreatic cancer and other important cancers,” said Dominique Dugourd, Vice President Research and Development, Soricimed Biopharma Inc. “It is our hope that our commitment to research will eventually yield a novel therapy for patients with significant unmet treatment needs.”
The single arm, open label study of SOR-C13 (Clinicaltrials.gov identifier NCT03784677), will enroll approximately 36 patients with advanced solid tumor cancers with an emphasis on enrolling those patients with late-stage pancreatic cancer. The study’s primary objective is to define a maximum tolerated dose (MTD) for SOR-C13 and further define its safety profile. Secondary objectives include the evaluation of clinical response to SOR-C13 and to determine predictive biomarkers in patients who have achieved objective responses. The initial dose escalation cohorts will be followed by an expansion cohort to monitor clinical response.
To learn more about the clinical trial visit: https://clinicaltrials.gov/ct2/show/NCT03784677
About SOR-C13: SOR-C13 is a selective inhibitor of TRPV6, a calcium oncochannel over-expressed by solid tumour cancers. SOR-C13 binds with high affinity and selectivity and disrupts the function of TRPV6. TRPV6 plays a central role in a biochemical cascade that results in the upregulation of an array of pro-cancerous genes. TRPV6 is considered to be an important target for novel anticancer therapy. SOR-C13 is the first highly specific TRPV6 inhibitor to be identified and taken into clinical development.
About Soricimed Biopharma: Soricimed Biopharma Inc., is a private, clinical-stage company focused on developing first-in-class targeted cancer therapies. Our lead drug candidate, SOR-C13, completed a multi-center Phase 1 trial in late-stage solid tumor cancer. SOR-C13 was shown to be safe and well tolerated with over half of the patients treated having stable disease after 2 treatment cycles. Two patients with stage IV pancreatic cancer showed tumor size reduction with one patient achieving a 30% reduction in the size of the primary pancreatic tumor. The U.S. FDA granted orphan-drug designation to SOR-C13 for the treatment of ovarian cancer and for the treatment of pancreatic cancer. Privately held, Soricimed is funded through private investors and various programs from the Governments of Canada and New Brunswick. For more information please visit, www.soricimed.com
For More Information:
Julie A. Fotheringham
Partner, HAGEMAN Communication
SOURCE: Soricimed Biopharma Inc.